Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 2, 2008, Pages 260-270

  Johnson, Steven M ^a   Connelly, Stephen ^a   Wilson, Ian A ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOXAZOLE DERIVATIVE; CYCLOOXYGENASE 1; PREALBUMIN; THYROID HORMONE RECEPTOR;

AMYLOIDOSIS; ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; PROTEIN AGGREGATION; STRUCTURE ACTIVITY RELATION;

AMYLOID; BENZOXAZOLES; CRYSTALLOGRAPHY, X-RAY; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; HUMANS; LIVER; MODELS, MOLECULAR; PREALBUMIN; PROTEIN CONFORMATION; RECEPTORS, THYROID HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 38349124133     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0708735     Document Type: Article

References (66)

1. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2817-2822.
2. Sekijima, Y.; Wiseman, R. L.; Matteson, J.; Hammarstrom, P.; Miller, S. R.; Sawkar, A. R.; Balch, W. E.; Kelly, J. W. The biological and chemical basis for tissue selective amyloid disease. Cell 2005, 121, 73-85.
3. McCarthy, R. E.; Kasper, E. K. A review of the amyloidoses that infiltrate the heart. Clin. Cardiol. 1998, 21, 547-552.
4. Johnson, S. M.; Wiseman, R. L.; Sekijima, Y.; Green, N. S.; Adamski-Werner, S. L.; Kelly, J. W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: A focus on the transthyretin amyloidoses. Acc. Chem. Res. 2005, 38, 911-921.
5. Jacobson, D. R.; Pastore, R. D.; Yaghoubian, R.; Kane, I.; Gallo, G.; Buck, F. S.; Buxbaum, J. N. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N. Engl. J. Med. 1997, 336, 466-473.
6. Plante-Bordeneuve, V.; Said, G. Transthyretin related familial amyloid polyneuropathy. Curr. Opin. Neurol. 2000, 13, 569-573.
7. Holmgren, G.; Ericzon, B. G.; Groth, C. G.; Steen, L.; Suhr, O.; Andersen, O.; Wallin, B. G.; Seymour, A.; Richardson, S.; Hawkins, P. N. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993, 341, 1113-1116.
8. Tan, S. Y.; Pepys, M. B.; Hawkins, P. N. Treatment of amyloidosis. Am. J. Kidney Dis. 1995, 26, 267-285.
9. Suhr, O. B.; Herlenius, G.; Friman, S.; Ericzon, B. G. Liver transplantation for hereditary transthyretin amyloidosis. Liver Transplant. 2000, 6, 263-276.
10. Olofsson, B. O.; Backman, C.; Karp, K.; Suhr, O. B. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. Transplantation 2002, 73, 745-751.
11. Blake, C. C.; Geisow, M. J.; Oatley, S. J.; Rerat, B.; Rerat, C. Structure of prealbumin: Secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. J. Mol. Biol. 1978, 121, 339-356.
12. Hornberg, A.; Eneqvist, T.; Olofsson, A.; Lundgren, E.; Sauer-Eriksson, A. E. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. J. Mol. Biol. 2000, 302, 649-669.
13. Foss, T. R.; Kelker, M. S.; Wiseman, R. L.; Wilson, I. A.; Kelly, J. W. Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 2005, 347, 841-854.
14. Monaco, H. L.; Rizzi, M.; Coda, A. Structure of a complex of two plasma proteins: Transthyretin and retinol-binding protein. Science 1995, 268, 1039-1041.
15. Foss, T. R.; Wiseman, R. L.; Kelly, J. W. The pathway by which the tetrameric protein transthyretin dissociates. Biochemistry 2005, 44, 15525-15533.
16. Neumann, P.; Cody, V.; Wojtczak, A. Structural basis of negative cooperativity in transthyretin. Acta Biochim. Pol. 2001, 48, 867-875.
17. Stockigt, J. R. Thyroid Hormone Binding and Metabolism. In Endocrinology, 4th edition; Degroot, L. J., Jameson, J. L., Eds.; W. B. Saunders Co.: Philadelphia, PA, 2001; pp 1314-1326.
18. Klabunde, T.; Petrassi, H. M.; Oza, V. B.; Raman, P.; Kelly, J. W.; Sacchettini, J. C. Rational design of potent human transthyretin amyloid disease inhibitors. Nat. Struct. Biol. 2000, 7, 312-321.
19. Hammarstrom, P.; Wiseman, R. L.; Powers, E. T.; Kelly, J. W. Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003, 299, 713-716.
20. Wiseman, R. L.; Johnson, S. M.; Kelker, M. S.; Foss, T.; Wilson, I. A.; Kelly, J. W. Kinetic stabilization of an oligomeric protein by a single ligand binding event. J. Am. Chem. Soc. 2005, 127, 5540-5551.
21. Coelho, T.; Carvalho, M.; Saraiva, M. J.; Alves, I.; Almeida, M. R.; Costa, P. P. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met 30 and TTR Met 119. J. Rheumatol. 1993, 20, 179.
22. Coelho, T.; Chorao, R.; Sausa, A.; Alves, I.; Torres, M. F.; Saraiva, M. J. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromuscular Disord. 1996, 6, 27.
23. Hammarstrom, P.; Schneider, F.; Kelly, J. W. trans-Suppression of misfolding in an amyloid disease. Science 2001, 293, 2459-2462.
24. Miller, S. R.; Sekijima, Y.; Kelly, J. W. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab. Invest. 2004, 84, 545-552.
25. Johnson, S. M.; Petrassi, H. M.; Palaninathan, S. K.; Mohamedmohaideen, N. N.; Purkey, H.; Nichols, C.; Chiang, K. P.; Walkup, T.; Sacchettini, J. C.; Sharpless, K. B.; Kelly, J. W. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. J. Med. Chem. 2005, 48, 1576-1587.
26. Miroy, G. J.; Lai, Z.; Lashuel, H. A.; Peterson, S. A.; Strang, C.; Kelly, J. W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 15051-15056.
27. Oza, V. B.; Petrassi, H. M.; Purkey, H. E.; Kelly, J. W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 1-6.
28. Oza, V. B.; Smith, C.; Raman, P.; Koepf, E. K.; Lashuel, H. A.; Petrassi, H. M.; Chiang, K. P.; Powers, E. T.; Sachettinni, J.; Kelly, J. W. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J. Med. Chem. 2002, 45, 321-332.
29. Baures, P. W.; Peterson, S. A.; Kelly, J. W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 1998, 6, 1389-1401.
30. Baures, P. W.; Oza, V. B.; Peterson, S. A.; Kelly, J. W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. Bioorg. Med. Chem. 1999, 7, 1339-1347.
31. Adamski-Werner, S. L.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J. Med. Chem. 2004, 47, 355-374.
32. Purkey, H. E.; Palaninathan, S. K.; Kent, K. C.; Smith, C.; Safe, S. H.; Sacchettini, J. C.; Kelly, J. W. Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: Rationalizing rodent PCB toxicity. Chem. Biol. 2004, 11, 1719-1728.
33. Razavi, H.; Palaninathan, S. K.; Powers, E. T.; Wiseman, R. L.; Purkey, H. E.; Mohamedmohaideen, N. N.; Deechongkit, S.; Chiang, K. P.; Dendle, M. T.; Sacchettini, J. C.; Kelly, J. W. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem., Int. Ed. 2003, 42, 2758-2761.
34. Razavi, H.; Powers, E. T.; Purkey, H. E.; Adamski-Werner, S. L.; Chiang, K. P.; Dendle, M. T.; Kelly, J. W. Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 1075-1078.
35. Petrassi, H. M.; Klabunde, T.; Sacchettini, J. C.; Kelly, J. W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 2000, 122, 2178-2192.
36. Petrassi, H. M.; Johnson, S. M.; Purkey, H.; Chiang, K. P.; Walkup, T.; Jiang, X.; Powers, E. T.; Kelly, J. W. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: Kinetic stabilization of the native state. J. Am. Chem. Soc. 2005, 127, 6662-6671.
37. Purkey, H. E.; Dorrell, M. I.; Kelly, J. W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 5566-5571.
38. Glenner, G. G. Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts). N. Engl. J. Med. 1980, 302, 1333-1343.
39. Kumar, D.; Jacob, M. R.; Reynolds, M. B.; Kerwin, S. M. Synthesis and evaluation of anticancer benzoxazoles and benzimidazoles related to UK-1. Bioorg. Med. Chem. 2002, 10, 3997-4004.
40. Colon, W.; Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 1992, 31, 8654-8660.
41. Hurshman, A. R.; White, J. T.; Powers, E. T.; Kelly, J. W. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004, 43, 7365-7381.
42. Glaser, K.; Sung, M. L.; O'Neill, K.; Belfast, M.; Hartman, D.; Carlson, R.; Kreft, A.; Kubrak, D.; Hsiao, C. L.; Weichman, B. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol. 1995, 281, 107-111.
43. Inoue, A.; Yamakawa, J.; Yukioka, M.; Morisawa, S. Filter-binding assay procedure for thyroid hormone receptors. Anal. Biochem. 1983, 134, 176-183.
44. Andrea, T. A.; Cavalieri, R. R.; Goldfine, I. D.; Jorgensen, E. C. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19, 55-63.
45. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16789-16794.
46. Hilal, S. H.; Karickhoff, S. W.; Carreira, L. A. A rigorous test for SPARCs chemical reactivity models: Estimation of more than 4300 ionization pKa's. Quant. Struct.-Act. Relat. 1995, 14, 348-355.
47. Mancini, J. A.; Riendeau, D.; Falgueyret, J. P.; Vickers, P. J.; O'Neill, G. P. Arginine 120 of prostaglandin G/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety. J. Biol. Chem. 1995, 270, 29372-29377.
48. Garavito, R. M.; Mulichak, A. M. The structure of mammalian cyclooxygenases. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 183-206.
49. Picot, D.; Loll, P. J.; Garavito, R. M. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994, 367, 243-249.
50. Bhattacharyya, D. K.; Lecomte, M.; Rieke, C. J.; Garavito, M.; Smith, W. L. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1. J. Biol. Chem. 1996, 271, 2179-2184.
51. Baxter, J. D.; Goede, P.; Apriletti, J. W.; West, B. L.; Feng, W.; Mellstrom, K.; Fletterick, R. J.; Wagner, R. L.; Kushner, P. J.; Ribeiro, R. C.; Webb, P.; Scanlan, T. S.; Nilsson, S. Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. Endocrinology 2002, 143, 517-524.
52. Wagner, R. L.; Apriletti, J. W.; McGrath, M. E.; West, B. L.; Baxter, J. D.; Fletterick, R. J. A structural role for hormone in the thyroid hormone receptor. Nature 1995, 378, 690-697.
53. Wagner, R. L.; Huber, B. R.; Shiau, A. K.; Kelly, A.; Cunha Lima, S. T.; Scanlan, T. S.; Apriletti, J. W.; Baxter, J. D.; West, B. L.; Fletterick, R. J. Hormone selectivity in thyroid hormone receptors. Mol. Endocrinol. 2001, 15, 398-410.
54. Scanlan, T. S.; Yoshihara, H. A.; Nguyen, N. H.; Chiellini, G. Selective thyromimetics: tissue-selective thyroid hormone analogs. Curr. Opin. Drug Discovery Dev. 2001, 4, 614-622.
55. Weatherman, R. V.; Fletterick, R. J.; Scanlan, T. S. Nuclear-receptor ligands and ligand-binding domains. Annu. Rev. Biochem. 1999, 68, 559-581.
56. Wiseman, R. L.; Green, N. S.; Kelly, J. W. Kinetic stabilization of an oligomeric protein under physiological conditions demonstrated by a lack of subunit exchange: Implications for transthyretin amyloidosis. Biochemistry 2005, 44, 9265-9274.
57. McCammon, M. G.; Scott, D. J.; Keetch, C. A.; Greene, L. H.; Purkey, H. E.; Petrassi, H. M.; Kelly, J. W.; Robinson, C. V. Screening transthyretin amyloid fibril inhibitors: Characterization of novel multiprotein, multiligand complexes by mass spectrometry. Structure 2002, 10, 851-863.
58. Lashuel, H. A.; Wurth, C.; Woo, L.; Kelly, J. W. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 1999, 38, 13560-13573.
59. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
60. Green, N. S.; Palaninathan, S. K.; Sacchettini, J. C.; Kelly, J. W. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. J. Am. Chem. Soc. 2003, 125, 13404-13414.
61. Storoni, L. C.; McCoy, A. J.; Read, R. J. Likelihood-enhanced fast rotation functions. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60 (Pt 3), 432-438.
62. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53 (Pt 3), 240-255.
63. Lovell, S. C.; Davis, I. W.; Arendall, W. B.3rd; de Bakker, P. I.; Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins 2003, 50 (3), 437-450.
64. Vriend, G. WHAT IF: A molecular modeling and drug design program. J. Mol. Graph. 1990, 8, 52-56.
65. Terwilliger, T. C. Automated main-chain model building by template matching and iterative fragment extension. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, 59 (Pt 1), 38-44.
66. Laskowski, R.; MacArthur, M.; Moss, D.; Thornton, J. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.